Please assess the completion status of the following clinical trial:

Trial Title: Development of A Novel Anti-Hyperglycemic Agent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. History of type 2 diabetes mellitus who are na ve to hypoglycemic treatment, inadequately controlled by diet and exercise alone or oral medications.~2. Hemoglobin A1c level of 6.5 % to 8.0 % inclusive. Subjects not taking hypoglycemic drugs with HgbA1c of 6.0% to 6.5% must have a diagnosis of Diabetes Mellitus (DM).~3. Fasting blood glucose levels reasonably stable for at least 2 months or during the two-week lead-in-period.~4. Ethnicity: All ethnic groups.~5. Gender: Both men and women.~6. Female with reproductive potential must not be pregnant or lactating, and using reliable contraception methods.~7. Age \>18 years old.~Exclusion Criteria:~1. Taking insulin.~2. History of diabetic ketoacidosis or hyper osmolar non-ketotic coma.~3. Diabetes Mellitus related end-organ damage:~   * Evidence of diabetic autonomic and peripheral neuropathy~  * Diabetic proliferative retinopathy, based on eye exam by ophthalmologist~  * Diabetes nephropathy defined by \> 500 mg/24 hour urinary albumin excretion~4. Any disease likely to limit life span and/or increase risks of interventions:~   * Screening carotid B-mode ultrasound indicating clinically significant stenos in the common carotid arteries requiring intervention by angioplasty or resection.~  * Cancer treatment in the past 5 years, with the exception of cancers that have been cured, and carry a good prognosis.~  * Infectious disease: HIV positivity, active tuberculosis, or pneumonia.~5. Cardiovascular disease:~   * Hospitalization for treatment of heart disease in the past 12 months.~  * New York Heart Association Functional Class \> 2.~  * Left Bundle branch block on EKG.~  * Third degree atrioventricular block on EKG.~  * Uncontrolled hypertension with average systolic blood pressure of \> 160 mmHg on two screening visits and diastolic blood pressure \> 95 mmHg on two screening visit.~  * Pulse rate \> 95 beats per minute on both screening visits.~  * Stroke or transient ischemic attack in the past 12 months.~6. Gastrointestinal disease:~   * Chronic hepatitis or cirrhosis.~  * Episode of alcoholic hepatitis or alcoholic pancreatitis.~  * Inflammatory bowel disease requiring treatment in the past 12 months.~  * Recent or significant abdominal surgery (e.g. gastrectomy, gastric bypass).~7. Renal disease: Serum creatinine \> 1.5 mg/dL for men, and \> 1.4 mg/dL for women.~8. Lung disease:~   * Chronic obstructive airway disease or asthma requiring daily therapy.~  * Use of home oxygen.~9. Anemia: Hematocrit of \< 36.0% in men or \< 33% in women.~10. Conditions or behaviors likely to affect the conduct of the study~    * Unable or unwilling to give informed consent.~   * Unable to communicate with the clinic staff.~   * Unwilling to accept treatment assignment by randomization.~   * Weight loss of \> 10% in the past 6 months.~   * Unable to walk without any assisted device.~   * Major psychiatric disorder which would impede conduct of the research.~   * Excessive alcohol intake (more than 2 drinks/day)~11. Medications~    * Psychoactive agents such as Monoamine oxidase inhibitors and Antidepressive agents (lithium, prozac, zoloft, serzone, paxil, effexor)~   * Systemic use of glucocorticoids steroids within previous 6 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclo-Z (minimally effective) (Type: EXPERIMENTAL): 3mg CHP plus 20mg zinc containing gel capsule;
- Cyclo-Z (maximally effective) (Type: EXPERIMENTAL): 9mg CHP plus 20mg zinc containing gel capsule;
- Cyclo-Z (not additionally effective) (Type: EXPERIMENTAL): 15mg CHP plus 20mg zinc containing gel capsule
- Placebo (for CHP) (Type: PLACEBO_COMPARATOR): Placebo capsules containing no zinc or CHP

Based on this trial design, predict the completion outcome and termination type (if applicable).